274 related articles for article (PubMed ID: 33419761)
21. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
22. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
[TBL] [Abstract][Full Text] [Related]
23. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
24. Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
Perez-Gracia JL; Labiano S; Rodriguez-Ruiz ME; Sanmamed MF; Melero I
Curr Opin Immunol; 2014 Apr; 27():89-97. PubMed ID: 24485523
[TBL] [Abstract][Full Text] [Related]
25. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
[TBL] [Abstract][Full Text] [Related]
26. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
27. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
28. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
[TBL] [Abstract][Full Text] [Related]
29. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
31. [Progression of immunotherapy in gastric cancer].
Wei X; Xu R
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
[TBL] [Abstract][Full Text] [Related]
32. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
34. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
35. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
36. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
38. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Sandin LC; Eriksson F; Ellmark P; Loskog AS; Tötterman TH; Mangsbo SM
Oncoimmunology; 2014 Jan; 3(1):e27614. PubMed ID: 24701377
[TBL] [Abstract][Full Text] [Related]
39. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
[TBL] [Abstract][Full Text] [Related]
40. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
